No added benefits in slowing MS disability progression were found in a study that increased Ocrevus dosing to 2-3 times the ...

Swiss pharma giant Roche RHHBY faced a setback in its efforts to develop a higher dose of multiple sclerosis drug Ocrevus ...

“These findings reaffirm that the current Ocrevus IV 600 mg is optimally dosed to significantly slow disability progression,” ...

Roche said on Wednesday that a trial testing higher doses of its multiple sclerosis drug Ocrevus did not show an efficacy ...

The study aimed to determine whether treatment with high dose ocrelizumab would provide an additional benefit in slowing disability progression.

Swiss pharma major Roche (ROG: SIX) said a higher-dose version of its top-selling multiple sclerosis drug Ocrevus ...

Roche’s phase III MUSETTE trial of Ocrevus high dose in people with relapsing multiple sclerosis fails to meet primary endpoint: Basel Friday, April 4, 2025, 11:00 Hrs [IST] Roc ...

Roche Holdings AG (OTC:RHHBY) on Wednesday announced data from MUSETTE Phase 3 trial of a high dose of Ocrevus (ocrelizumab) ...

- The trial did not meet its primary endpoint; results support Ocrevus IV 600 mg as the optimal dose to slow disability progression - - High dose was well tolerated with an overall comparable ...

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...

The MUSETTE Phase 3 trial showed no added benefit of high-dose Ocrevus over the standard 600 mg IV dose in slowing disability progression. Ocrevus 600 mg IV maintained low disability progression ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase III MUSETTE trial ...